To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA approval for FSAD. Market research estimates ...

Daré Bioscience, in collaboration with Strategic Science & Technologies, announced plans for a Phase 3 clinical study of Sildenafil Cream, 3.6%, aimed at treating female sexual arousal disorder ...

Dare Bioscience (DARE) announced plans for a Phase 3 study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for ...

Erectile dysfunction (ED) is a common condition, and many people find that it is treatable with Viagra — sometimes called the “little blue pill” — and its generic form, sildenafil.

Dare Bioscience (DARE) announced that additional data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil ...

FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to ...

FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments for FSAD; Daré's Sil ...

Daré Bioscience, Inc., a company at the forefront of female health and wellness innovation, has recently disclosed its Phase 3 clinical development plans for Sildenafil Cream, 3.6%, intended for ...

DARE Dare Bioscience Inc Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) ...